HR+/HER2− Breast Cancer

Identification and Treatment of Patients With Hormone Receptor–Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE Study Long-Term Outcomes
Identification and Treatment of Patients With Hormone Receptor–Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE Study Long-Term Outcomes
Clinical Trials, HR+/HER2− Breast Cancer, Breast Cancer
Special Issues and Supplements — February 24, 2025
We are pleased to announce the release of our next issue of Clinical Trials to Clinical Practice. This article provides expert commentary from Joyce A. O’Shaughnessy, MD, on the use of endocrine therapy with or without adjuvant abemaciclib for patients with high-risk, hormone receptor (HR)-positive, HER2-negative early breast cancer.
Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path
Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path
Breast Cancer, Resources, HR+/HER2− Breast Cancer
Resources — September 9, 2024
The Navigator Guide: Walking With a Patient Down the Early Breast Cancer Path is a resource that oncology nurses and navigators can use to assist patients and caregivers in the fight against early-stage breast cancer. Oncology nurses and navigators guide patients through their treatment journey from time of diagnosis into survivorship, providing education, resources, and support.
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
ESMO Early Breast Cancer
Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer
By Nadia Harbeck, MD, PhD
Interview with the Innovators, Breast Cancer, HR+/HER2− Breast Cancer
Video Library — December 18, 2023
This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
Analysis of Ribociclib plus Letrozole in Male Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer, HR+/HER2− Breast Cancer
Web Exclusives — December 18, 2020
Subgroup analysis of the phase 3b CompLEEment-1 clinical trial supports the use of ribociclib combined with letrozole in HR-positive, HER2-negative advanced breast cancer male patients based on demonstrated efficacy and safety.
Evaluation of an Alternative Schedule of Palbociclib in Patients with HR-Positive, HER2-Negative Metastatic Breast Cancer
Breast Cancer, HR+/HER2− Breast Cancer
Web Exclusives — December 15, 2020
An alternative schedule of palbociclib reduced grade ≥3 neutropenia and showed efficacy data comparable with previous reports.
Study of Adherence to and Patient Satisfaction with Exemestane and Everolimus in Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer, HR+/HER2− Breast Cancer
Web Exclusives — December 15, 2020
Findings from this study show that based on the adjusted adherence rate of the combination therapy of exemestane and everolimus, a low-rate adherence was observed.
Updated NCCN Breast Cancer Treatment Guideline Reflects Expanding Treatment Options for HR-Positive, HER2-Negative Disease
Breast Cancer, Highlights From NCCN, NCCN Guidelines, HR+/HER2− Breast Cancer
May 2019 Vol 10, No 5 — May 7, 2019
Options for the treatment of patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer are expanding.
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Breast Cancer, FDA Updates, HR+/HER2− Breast Cancer
2018 Third Annual Oncology Guide to New FDA Approvals — June 6, 2018
On March 13, 2017, the US Food and Drug Administration (FDA) approved ribociclib (Kisqali; Novartis), an oral CDK4/CDK6 inhibitor, in combination with letrozole for the treatment of postmenopausal women with HR-positive, HER2-negative advanced breast cancer.

Journal of Oncology Navigation & Survivorship

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

Connect with Us

 
 
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.